Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 836-836
Open Access | Times Cited: 25

Showing 25 citing articles:

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
Heng‐Chih Pan, Jui‐Yi Chen, Hsing‐Yu Chen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 5
Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications
Xinyu Zhang, Chao Cao, Fei Zheng, et al.
Cardiovascular Drugs and Therapy (2025)
Open Access
Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway
Can Wang, Zhenhua Wu, Jiaying Zhou, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 3
Open Access
Advances in Therapeutic Targets and Traditional Chinese Medicine for Cardiomyopathy
Shuo Yang, Shuai‐nan Zhang, Xu‐zhao Li
Phytotherapy Research (2025)
Closed Access
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
Abdelilah Arredouani
Pharmacology & Therapeutics (2025), pp. 108824-108824
Closed Access
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access
Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression
Meiling Yan, Kaibin Lin, Dong Huang, et al.
Endocrine (2024) Vol. 84, Iss. 3, pp. 969-979
Closed Access | Times Cited: 3
Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome
Zorislava Bajić, Tanja Šobot, Ljiljana Amidžić, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1207-1207
Open Access | Times Cited: 3
The latest trends in peptide drug discovery and future challenges
László Ötvös
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 8, pp. 869-872
Open Access | Times Cited: 3
Omarigliptin/rosinidin combination ameliorates cyclophosphamide-induced lung toxicity in rats: The interaction between glucagon-like peptide-1, TXNIP/NLRP3 inflammasome signaling, and PI3K/Akt/FoxO1 axis
Maaly A. Abd Elmaaboud, Ahmed M Kabel, Hany M Borg, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117026-117026
Open Access | Times Cited: 3
The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects
Piotr Krajewski, Aleksandra Złotowska, Jacek C. Szepietowski
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6292-6292
Open Access | Times Cited: 3
GLP-1 in hypothalamic paraventricular nucleus promotes sympathetic activation and hypertension
Xiaoyu Xu, Jing-Xiao Wang, Jun-Liu Chen, et al.
Journal of Neuroscience (2024) Vol. 44, Iss. 21, pp. e2032232024-e2032232024
Closed Access | Times Cited: 2
Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects
Anastasios Lymperopoulos, Jordana I. Borges, Renee A. Stoicovy
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 693-693
Open Access | Times Cited: 2
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice
Yuwen Liu, Ren Luo, Anqi Liu, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 2
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Francisco Epelde
Medicina (2024) Vol. 60, Iss. 12, pp. 1986-1986
Open Access | Times Cited: 2
Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
Dalgisio Lecis, Francesca Romana Prandi, Lucy Barone, et al.
Biomolecules (2023) Vol. 13, Iss. 12, pp. 1695-1695
Open Access | Times Cited: 5
Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome
Marko Ravic, Ivan Srejović, Jovana Novaković, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 525-525
Open Access | Times Cited: 1
Exendin-4 exhibits cardioprotective effects against high glucose-induced mitochondrial abnormalities: Potential role of GLP-1 receptor and mTOR signaling
Warisara Parichatikanond, Sudhir Pandey, Supachoke Mangmool
Biochemical Pharmacology (2024), pp. 116552-116552
Open Access | Times Cited: 1
Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects
Renee A. Stoicovy, Natalie Cora, Arianna Perez, et al.
Inflammation Research (2024)
Closed Access | Times Cited: 1
Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway
Kaibin Lin, Wang Ai, Changlin Zhai, et al.
British Journal of Pharmacology (2024)
Closed Access | Times Cited: 1
GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
Marika Dębik, Łukasz Szydłowski, Klaudia Żurowska, et al.
Journal of Education Health and Sport (2024) Vol. 62, pp. 217-239
Open Access
Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
Chenyang Shi, Yijiong Tan, Shanshan Hu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2513-2516
Closed Access
Diabetes mellitus therapy in the light of oxidative stress and cardiovascular complications
Alaa A. Osman, Adrienn Seres-Bokor, Eszter Ducza
Journal of Diabetes and its Complications (2024) Vol. 39, Iss. 2, pp. 108941-108941
Closed Access
Page 1

Scroll to top